Briefing
Abstract GS3-06: Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer
The 12-month ctDNA detection rate was 27.3% (44/161). Seven patients relapsed without prior ctDNA detection. Of patients allocated to pembrolizumab, 23/32 (72%) already had metastatic disease on staging at the time of ctDNA detection. Only 5 patients started pembrolizumab; none achieved sustained ctDNA clearance, and 4 had recurred at analysis. In the observation group, median time to recurrence was 4.1 months. The therapeutic activity endpoint could not be assessed.
- Design: oral
- n: 208 registered; 171 with trackable mutations; 161 entered ctDNA surveillance
- Assay: digital PCR mutation tracking (1-2 patient-specific variants), as described in the companion full paper and later assay-comparison abstracts from the same trial